Sponsored by
The FDA just issued draft guidance outlining a new approval pathway for highly individualized therapies designed to treat ultra-rare diseases. The proposal introduces what the agency calls a "Plausible Mechanism Framework," aimed at situations where traditional large randomized trials are not feasible because patient populations are very small.
The draft guidance focuses on genome editing and RNA-based treatments, such as antisense oligonucleotides, that directly target a specific genetic or molecular abnormality causing disease. Instead of requiring large trials, the FDA would allow approvals based on strong biological rationale, well-documented natural history data, confirmation that the therapy successfully hits its intended target, and evidence of clinical benefit or validated biomarkers. The agency also suggests that related mutation-specific versions of a therapy could potentially be evaluated under shared master study protocols.
For the brain cancer community, this could be an important development. As tumors like glioblastoma are increasingly divided into smaller molecular subtypes (e.g. H3 G34 diffuse hemispheric glioma), some patients have rare or even unique mutations that are difficult to study in large trials. A more flexible, common sense regulatory approach could help accelerate development of precision therapies for these small groups while maintaining safety and scientific rigor.
The draft guidance, titled "Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause," is open for public comment for 60 days following publication in the Federal Register.
To submit a public comment, visit: https://www.regulations.gov, search for the guidance title and click "Comment."